Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS).
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 12 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.